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Although postmenopausal osteoporosis often occurs concurrently with diabetes, little is known about interactions between
estrogen deficiency and hyperglycemia in the skeletal system. In the present study, the effects of estrogen deficiency on the
development of biochemical, microstructural, and mechanical changes induced by streptozotocin-induced diabetes mellitus
(DM) in the rat skeletal system were investigated. The experiments were carried out on nonovariectomized (NOVX) and
ovariectomized (OVX) control and diabetic mature female Wistar rats. Serum levels of bone turnover markers (CTX-I and
osteocalcin) and 23 cytokines, bone mass and mineralization, histomorphometric parameters, and mechanical properties of
cancellous and compact bone were determined. The results were subjected to two-way ANOVA and principal component
analysis (PCA). Estrogen deficiency induced osteoporotic changes, with increased bone resorption and formation, and
worsening of microstructure (femoral metaphyseal BV/TV decreased by 13.0%) and mechanical properties of cancellous bone
(the maximum load in the proximal tibial metaphysis decreased by 34.2%). DM in both the NOVX and OVX rats decreased
bone mass, increased bone resorption and decreased bone formation, and worsened cancellous bone microarchitecture (for
example, the femoral metaphyseal BV/TV decreased by 17.3% and 18.1%, respectively, in relation to the NOVX controls) and
strength (the maximum load in the proximal tibial metaphysis decreased by 35.4% and 48.1%, respectively, in relation to the
NOVX controls). Only in the diabetic rats, profound increases in some cytokine levels were noted. In conclusion, the changes
induced by DM in female rats were only slightly intensified by estrogen deficiency. Despite similar effects on bone
microstructure and strength, the influence of DM on the skeletal system was based on more profound systemic homeostasis
changes than those induced by estrogen deficiency.
1. Introduction
Osteoporosis is a serious public health problem, leading, in
developed countries, to fragility fractures in one of three
women and in one of five men aged over 50 years [1]. Painful
and disabling osteoporotic fractures not only worsen the qual-
ity of life but lead to premature death [2]. The main cause of
osteoporosis is estrogen deficiency in postmenopausal women;
however, other factors contribute to the development of the
disease, including, among others, immobilization, administra-
tion of glucocorticosteroids, or diabetes [3].
There are two main types of diabetes: type 1 diabetes
(T1D), with β-cell destruction and insulin deficiency, and
type 2 diabetes (T2D), with progressive defect of insulin
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secretion on the background of insulin resistance [4]. Both
types lead to numerous complications, including disorders
of bone metabolism with increased fracture rate [5–7].
T1D, concerning about 5-10% of all diabetes cases, occurs
in younger people, whereas T2D usually develops at a later
age [4]. It is likely for T2D to occur concurrently with estro-
gen deficiency in postmenopausal women. However,
increased life expectancy in T1D patients, resulting from
the progress in the insulin therapy, increases the probability
of its coexistence with postmenopausal osteoporosis.
It has been estimated that the trajectories of the epidemi-
ology of diabetes and osteoporosis are similar, and the
increase in the number of diabetic patients will contribute
to the increase in the number of patients with osteoporosis
induced by diabetes [8]. The clinical data on interactions
between changes induced by estrogen deficiency and diabe-
tes, concerning the skeletal system, are not abundant [9].
Also, little is known about interactions between estrogen
deficiency and hyperglycemia in terms of effects on the skel-
etal system in experimental conditions in vivo.
Different experimental models are used in the preclinical
bone pharmacology to investigate the effects of potential
treatments on the development of osteoporotic changes.
The well-established and almost fully adequate model of
estrogen deficiency-induced postmenopausal osteoporosis is
a model of bilaterally ovariectomized rats or mice [10]. The
most widely used experimental model of T1D is diabetes
induced by the administration of streptozotocin (STZ) in rats
or mice (single i.v. or i.p. injection), which induces the
destruction of pancreatic β-cells and severe hyperglycemia
[11, 12]. As far as T2D is concerned, there are numerous dif-
ferent murine models used, none of them adequately mirror-
ing the changes developing in the disease [13, 14].
The number of reports on the skeletal effects of diabetes
in experimental models of estrogen deficiency is scarce. Up
to very recently, there were early reports available, concern-
ing mostly the effect on bone mineral density (BMD) and
bone turnover markers [15–19]. However, in the last years,
several reports have been published, shedding more light on
the pathogenesis of changes developing under the influence
of both pathologies in rodents [20–27].
The aim of the study was to evaluate the effects of estro-
gen deficiency on the development of biochemical, micro-
structural, and mechanical changes induced by T1D in the
rat skeletal system. Taking into account the established role
of some cytokines in the regulation of bone remodeling, we
investigated the effects of estrogen deficiency and diabetes
on the serum levels of a wide panel of cytokines, including
both proinflammatory and anti-inflammatory ones.
2. Materials and Methods
2.1. Animals and Chemicals. Female Wistar rats were
obtained from the Center of Experimental Medicine, Medical
University of Silesia, Katowice, Poland. All procedures were
approved by the Local Ethics Commission, Katowice, Poland
(permission numbers: 9/2015 and 149/2015). The rats were
maintained under monitored standard laboratory conditions
according to the European Union guidelines (directive
2010/63/EU), in standard plastic cages (Tecniplast, Buguggi-
ate, Italy), four-five rats per cage, under a 12h light–12h dark
cycle (light on 7 : 00 a.m.). The experiment started after the
acclimatization. The rats were 3 months old.
During the experiment, the following drugs were used: a
drug used for the induction of T1D: streptozotocin (STZ;
Cayman Chemical Company, Ann Arbor, MI, USA); drugs
used in order to mark the calcification front: tetracycline
hydrochloride (Sigma-Aldrich Co., St. Louis, MO, USA)
and calcein (Sigma-Aldrich Co., St. Louis, MO, USA); drugs
used for general anesthesia: ketamine (Bioketan; Vetoquinol
Biowet Sp. z o.o., Gorzów Wielkopolski, Poland) and xyla-
zine (Xylapan; Vetoquinol Biowet Sp. z o.o., Gorzów Wielk-
opolski, Poland). The rats were fed a standard laboratory
diet (Labofeed B; Wytwórnia Pasz “Morawski”, Kcynia,
Poland).
The experiments were performed on rats divided into the
following groups (n = 9 − 10):
(I) – Nonovariectomized control rats (NOVX)
(II) – Ovariectomized control rats (OVX)
(III) – Nonovariectomized rats with type 1 diabetes
(DM-NOVX)
(IV) – Ovariectomized rats with type 1 diabetes (DM-
OVX)
The initial body mass of the rats before the start of the
procedures was similar. The bilateral ovariectomy was per-
formed under ketamine-xylazine (i.p.) anesthesia. T1D was
induced by a single dose of STZ (60mg/kg i.p., dissolved in
0.1M citrate buffer), administered three days after the bilat-
eral ovariectomy was performed. A week after the ovariec-
tomy, the first measurement of nonfasting blood glucose
level took place in order to confirm the development of dia-
betes, using an Accu-Chek Performa Nano glucometer
(Roche Diagnostics GmbH, Mannheim, Germany) and
Accu-Chek Performa test strips (Roche Diabetes Care,
Mannheim, Germany). The blood samples for the measure-
ment were taken from the tail vessels of conscious rats by cut-
ting the tail tip. Rats with the blood glucose level above
400mg/100mL were regarded as diabetic. Nonfasting blood
glucose level was then measured once a week. The rats were
weighed once a week, and, furthermore, on the day before
the end of the experiment. Moreover, since all the rats served
as controls in a bigger study, they were subcutaneously
administered saline (1mL/kg/day), starting one week after
the ovariectomy. In order to label the calcification front, tet-
racycline hydrochloride at a dose of 20mg/kg i.p. was admin-
istered seven days after the ovariectomy, and then calcein
(10mg/kg i.p.) was administered three weeks after the
administration of tetracycline hydrochloride.
The experiment was terminated five weeks after the
ovariectomy. The rats were fasted, anesthetized with the i.p.
administration of the mixture of ketamine and xylazine,
and sacrificed by cardiac exsanguination. After the vital func-
tions ceased, the liver, thymus, uterus, adrenal glands, and
bones (right and left tibias, right and left femurs, L4 vertebra)
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were isolated. The soft organs and left bones and vertebras,
after cleaning from soft tissues, were weighed on an Ohaus
analytical balance model Adventurer Pro type AV264CM
(Ohaus Europe GmbH, Greifensee, Switzerland). The length
and diameter in the midlength of the left tibias and left
femurs were measured using a digital caliper (VOREL
15240, Toya, Wrocław, Poland). The left femurs, left tibias,
and the proximal part of the right femurs, cut in the middle
of the bone length, were wrapped in gauze soaked with saline
and stored below –20°C [28]. Blood serum was frozen at –
80°C until subjected to further measurements.
2.2. Bone Mechanical Properties Studies. The mechanical
properties of bones were evaluated with an Instron 3342
500N apparatus (Instron, Norwood, MA, USA). Bluehill 2
software (version 2.14; Instron, Norwood, MA, USA) was
used for data analysis. Mechanical properties were assessed
with the use of three-point bending tests in the left proximal
tibial metaphysis and the left femoral diaphysis (test param-
eters: displacement rate of 0.01mm/s, sampling rate of
100Hz), as previously described [28–30].
To evaluate the strength of the proximal tibial metaphy-
sis, the proximal epiphysis was removed, and the load was
applied perpendicularly to the long axis of the bone 3mm
from its proximal edge [29, 30]. The following parameters
were determined based on the load-displacement curves
obtained for each bone: Young’s modulus and the load, dis-
placement, energy, and stress for the yield point (0.05% off-
set), maximum load point, and fracture point. In order to
calculate the intrinsic (independent of bone size and shape)
parameters: stress and Young’s modulus, the tibial metaphy-
sis was assumed to be a circular beam and its diameter mea-
sured with a digital caliper.
To determine the mechanical properties of the femoral
diaphysis [28, 30], the load was applied perpendicularly to
the diaphysis in the middle of the bone length, with the dis-
tance between the supporting points of 16mm. The same
parameters were determined as for the tibial metaphysis;
the calculations were based on the assumption that the fem-
oral diaphysis was an elliptical pipe. For calculations, the
internal and external diameters of the right femoral diaphysis
were measured in histological preparations of the transverse
cross-section of the right femur in the midlength, with the
use of the set consisting of a Carl Zeiss Axio Imager.A1
microscope (Carl Zeiss, Göttingen, Germany) connected
with an Olympus DP71 camera (Olympus, Tokyo, Japan)
and a computer with OsteoMeasure XP 1.3.0.1 software
(OsteoMetrics Inc., Decatur, GA, USA), with a graphics tab-
let (model Cintiq 22HD; Wacom, Kazo, Japan).
The strength of the femoral neck was studied using a
compression test [30]. The load was applied to the head of
the femur along the long axis of the bone. The maximum
load (inducing fracture) was measured.
2.3. Bone Composition and Mineralization Studies. After per-
forming the mechanical tests, left tibias and femurs and L4
vertebras were lyophilized for ten days in FreeZone 6 lyoph-
ilizer (temperature: –51°C, pressure: 0.03 mBa; Labconco,
Kansas City, MO, USA) and then mineralized at 640°C for
48 hours in a muffle furnace L9/11/C6 (Nabertherm, Lilien-
thal, Germany). The lyophilized and mineralized bones were
weighed on an analytical balance Adventurer Pro type
AV264CM (Ohaus Europe GmbH, Greifensee, Switzerland)
in order to determine the mass of bone mineral, water, and
organic substances in bones. The contents of bone mineral,
water, and organic substances were calculated as the ratios
to the bone mass. The ashed bones were dissolved in 6M
HCl and then diluted in distilled water to spectrophotometri-
cally determine the calcium and phosphorus contents in the
bone mineral, with the use of Pointe Scientific (Canton, MI,
USA) kits.
2.4. Bone Histomorphometric Studies. The measurements of
the transverse cross-sections of the tibial and femoral diaph-
ysis were performed on undecalcified, unstained slides, pre-
pared as previously described [30, 31]. The measurements
of the longitudinal cross-sections of the femoral metaphysis
were carried out on decalcified preparations which were
stained with hematoxylin and eosin [32]. The OsteoMeasure
system (OsteoMetrics Inc., Decatur, GA, USA) was used for
the histomorphometric measurements, and the data were
presented according to the American Society for Bone and
Mineral Research (ASBMR) standardized nomenclature
[33].
In the cancellous bone of the distal femoral metaphysis,
the following parameters were determined: bone volume to
tissue volume ratio (BV/TV), trabecular thickness (Tb.Th),
trabecular separation (Tb.Sp), and trabecular number
(Tb.N).
In cortical bone of the tibial and femoral diaphysis, the
transverse cross-sectional area of the whole diaphysis
(Tt.Ar), transverse cross-sectional area of the cortical bone
(Ct.Ar), transverse cross-sectional area of the marrow cavity
(Ma.Ar), and the Ma.Ar/Tt.Ar ratio were measured.
The periosteal and endosteal transverse growth (mineral
apposition rate; MAR) in the tibial and femoral diaphysis
were measured. However, the evaluation of the effect of dia-
betes on those parameters was impossible, because tetracy-
cline and calcein labels could be observed only in the
preparations of the nonovariectomized and ovariectomized
controls.
2.5. Biochemical Studies. Serum concentrations of bone turn-
over markers, osteocalcin (a marker of bone formation) and
C-terminal telopeptide fragments of type I collagen released
from bone during bone resorption (CTX-I), were studied
by the ELISA methods (Rat-MID Osteocalcin EIA and
RatLaps (CTX-I) EIA, respectively, Immunodiagnostic Sys-
tems Ltd., Boldon, Tyne andWear, UK). A microplate reader
Stat Fax 2100 (Awareness Technology, Inc., Palm City, FL,
USA) was used for the measurements.
Serum concentrations of calcium, inorganic phosphorus,
glucose, fructosamine, and biochemical parameters of lipid
metabolism (total cholesterol, high-density lipoprotein
(HDL) cholesterol, low-density lipoprotein (LDL) choles-
terol, and triglycerides) were determined spectrophotometri-
cally, using kits produced by Pointe Scientific (Canton, MI,
USA). Moreover, the concentration of advanced oxidation
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protein products (AOPP), a marker of oxidative protein
damage, was measured spectrophotometrically based on the
method of Witko-Sarsat et al. [34, 35]. The calibration curve
was prepared using chloramine T (Sigma-Aldrich, St. Louis,
MO, USA), and the absorbance was measured at the wave-
length of 340nm. The AOPP concentration was expressed
in μmol of chloramine T equivalents/L. The spectrophoto-
metric measurements were performed with the use of Tecan
Infinite M200 PRO microplate reader and Magellan 7.2 soft-
ware (Tecan Austria GmbH, Grödig, Austria).
The measurements of serum concentrations of 23 cyto-
kines were performed with the use of multiplex technology
of magnetic bids combined with antibodies (Bio-Plex Pro
Rat Cytokine 23-Plex Immunoassay; Bio-Rad Laboratories
Inc., Hercules, CA, USA), using Bio-Plex 200 system and
Bio-Plex Manager software (Bio-Rad). The full panel of 23
rat cytokines for which the technique was available was
investigated. The following cytokines were assayed: interleu-
kin-1α (IL-1α), IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-10, IL-
12p70, IL-13, IL-17A, IL-18, granulocyte colony-
stimulating factor (G-CSF), granulocyte-macrophage
colony-stimulating factor (GM-CSF), growth-regulated
oncogene/keratinocyte chemoattractant (GRO/KC), inter-
feron-γ (IFN-γ), macrophage colony-stimulating factor (M-
CSF), macrophage inflammatory protein-1a (MIP-1a), mac-
rophage inflammatory protein-3a (MIP-3a), regulated on
activation, normal T cell expressed and secreted (RANTES),
tumor necrosis factor α (TNF-α), vascular endothelial
growth factor (VEGF), and monocyte chemoattractant
protein-1 (MCP-1; monocyte chemotactic and activating
factor—MCAF).
2.6. Statistical Analysis. Results are presented as the mean ±
standard error of themean (SEM). Statistical analysis was
carried out with the use of two-way analysis of variance
(ANOVA), with the main effects of estrogen deficiency
(OVX) and type 1 diabetes (DM). In case of the statistical sig-
nificance of any of the main effects or their interaction, the
ANOVA was followed by Fisher’s Least Significant Differ-
ence (LSD) post hoc test (Statistica 13.1; Tibco Software
Inc., Palo Alto, CA, USA). p values < 0.05 were considered
significant.
Moreover, the principal component analysis (PCA) was
performed on the following groups of parameters:
(I) – Body mass gain and mass of internal organs: the
uterus, thymus, adrenals, and liver
(II) – Serum metabolic biochemical parameters: con-
centrations of nonfasting and fasting blood glu-
cose, triglycerides, total cholesterol, LDL
cholesterol, HDL cholesterol, and AOPP
(III) – Serum bone turnover parameters: CTX-I, osteo-
calcin, inorganic phosphorus, and total calcium
concentrations
(IV) – Bone mass and macrometric parameters: tibial
mass, length and diameter, femoral mass, length
and diameter, and vertebral mass
(V) – Bone composition and mineralization: the con-
tent of bone mineral, water, and organic sub-
stances in the tibia, femur, and vertebra
(calculated as the ratios of their mass to the bone
mass), content of calcium and phosphorus in the
bone mineral in the tibia, femur, and vertebra
(VI) – Histomorphometric parameters of compact
bone: Ma.Ar, Ct.Ar, Tt.Ar, and Ma.Ar/Tt.Ar in
the tibial and femoral diaphysis
(VII) – Histomorphometric parameters of cancellous
bone of the femoral metaphysis: BV/TV, BS/TV,
BS/BV, Tb.Th, Tb.Sp, and Tb.N
(VIII) – Mechanical properties of cancellous bone:
Young’s modulus, load, displacement, energy,
and stress for yield point, maximum load point,
and fracture point in the tibial metaphysis
(IX) – Mechanical properties of compact bone:
Young’s modulus, load, displacement, energy,
and stress for yield point, maximum load point,
and fracture point in the femoral diaphysis
(X) – Serum concentrations of 23 cytokines
The PCA was carried out using the PAST 3.26 software
[36, 37]. Correlation matrices were employed for data stan-
dardization. The correlation values presented on the graphs
are autoscaled based on the algorithm built into the software.
Statistical significance of the PCA results was evaluated using
two-way MANOVA (multivariate analysis of variance; Sta-
tistica 13.1). In case of the statistical significance of any of
the main effects or their interaction, further analysis for indi-
vidual axes (PC1, PC2) was performed, followed by Fisher’s
LSD post hoc test. Only significant post hoc differences
between DM-OVX versus DM-NOVX are mentioned in the
figure legends; all results—see Supplementary Material 1.
3. Results
3.1. General Parameters. At the end of the experiment, five
weeks after the bilateral ovariectomy surgery, the mean body
mass of the diabetic rats, both nonovariectomized and ovari-
ectomized, significantly decreased in relation to appropriate
control rats, whereas the mean body mass of the nondiabetic
ovariectomized rats significantly increased (Table 1).
The liver mass increased, and the mass of the uterus, thy-
mus, and adrenal glands decreased in the diabetic rats inde-
pendent of the estrogen status, whereas the uterus mass
decreased, and thymus mass increased in the nondiabetic
ovariectomized rats.
Both the nonovariectomized and ovariectomized rats
administered STZ developed diabetes, as indicated by pro-
foundly increased glucose and fructosamine levels in relation
to appropriate controls, moreover, significant disorders of
lipid metabolism were noted (Table 2). Estrogen deficiency
itself did not affect the parameters connected with glucose
metabolism; however, it increased the cholesterol and LDL
cholesterol levels. The estrogen-deficient diabetic rats had
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significantly increased the level of AOPP in relation to the
ovariectomized controls, indicating oxidative protein
damage.
The PCA indicated strong differences concerning the
body mass gain, internal organ mass, and serum biochemical
metabolic parameters between the diabetic and nondiabetic
rats, as well as the nonovariectomized and ovariectomized
rats (Figures 1 and 2, respectively).
3.2. Serum Bone Turnover Markers. Diabetes induced signif-
icant increases in the concentration of the bone resorption
marker CTX-I (by 503.9% in the nonovariectomized rats
and by 325.9% in the ovariectomized rats in relation to the
appropriate nondiabetic controls) and decreases in that of
the bone formation marker osteocalcin (by 51.5% in the non-
ovariectomized rats and by 72.7% in the ovariectomized rats
in relation to the appropriate nondiabetic controls)
(Figure 3). Estrogen deficiency induced a significant increase
in the osteocalcin concentration only in the nondiabetic rats
(by 78.7% in relation to the nonovariectomized controls); the
CTX-I level was insignificantly increased (by 54.0% in rela-
tion to the nonovariectomized controls). Diabetes induced
increases in the calcium concentrations and decreases in
the inorganic phosphorus concentrations, regardless of the
estrogen status (Table 2).
The PCA analysis indicated strong differences concern-
ing the serum concentrations of bone turnover markers, cal-
cium, and inorganic phosphorus between the diabetic and
nondiabetic rats, as well as the nonovariectomized and ovari-
ectomized rats (Figure 4).
3.3. Bone Mass, Macrometric Parameters, Composition, and
Mineralization. Regardless the estrogen status, the diabetic
rats had significantly decreased the bone mass, bone mineral




Ovariectomized (OVX) rats Two-way ANOVA
Control DM Control DM OVX DM OVXx DM
Initial body mass (g)& 226:9 ± 3:3 208:7 ± 3:7∗∗ 220:9 ± 4:5 207:4 ± 3:7∗∗∗X NS p < 0:001 NS
4-week body mass gain (g) 12:1 ± 1:7 −17:4 ± 4:1∗∗∗ 42:1 ± 5:2∗∗∗ −22:8 ± 5:6∗∗∗XXX p < 0:01 p < 0:001 p < 0:001
Uterus mass (g) 0:511 ± 0:054 0:171 ± 0:030∗∗∗ 0:096 ± 0:006∗∗∗ 0:095 ± 0:007∗∗∗ p < 0:001 p < 0:001 p < 0:001
Thymus mass (g) 0:297 ± 0:019 0:093 ± 0:014∗∗∗ 0:529 ± 0:030∗∗∗ 0:056 ± 0:011∗∗∗XXX p < 0:001 p < 0:001 p < 0:001
Liver mass (g) 5:656 ± 0:114 8:099 ± 0:329∗∗∗ 6:197 ± 0:180 7:926 ± 0:299∗∗∗XXX NS p < 0:001 NS
Adrenals mass (g) 0:078 ± 0:004 0:071 ± 0:004 0:073 ± 0:004 0:059 ± 0:003∗∗∗XX a p < 0:05 p < 0:01 NS
Bilateral ovariectomy was performed 5 weeks before the end of the experiment. Diabetes was induced 3 days after the ovariectomy by a single administration of
streptozotocin (60mg/kg i.p.). Results are presented as means ± SEM (n = 9 − 10). Two-way ANOVA followed by Fisher’s LSD test was used for evaluation of
the significance of the results. &Body mass one week after the ovariectomy; ∗∗p < 0:01, ∗∗∗p < 0:001—significantly different from the NOVX control rats;
Xp < 0:05, XXp < 0:01, XXXp < 0:001—significantly different from the OVX control rats; ap < 0:05—significantly different from the DM-NOVX rats.





Ovariectomized (OVX) rats Two-way ANOVA
Control DM Control DM OVX DM
OVXx
DM
Glucose (mg/100mL) 82:8 ± 2:7 561:4 ± 12:2∗∗∗ 82:9 ± 1:5 575:9 ± 12:5∗∗∗XXX NS p < 0:001 NS
Fructosamine (mM/L) 0:483 ± 0:010 1:106 ± 0:051∗∗∗ 0:491 ± 0:014 0:887 ± 0:111
∗∗∗XXX
a NS p < 0:001 NS
Triglycerides (mg/100mL) 35:8 ± 3:8 68:8 ± 7:3∗∗ 40:8 ± 2:2 89:1 ± 11:4∗∗∗XXX NS p < 0:001 NS
Cholesterol (mg/100mL) 47:5 ± 4:9 53:3 ± 3:1 65:7 ± 2:4∗∗∗ 69:8 ± 2:4∗∗∗aa p < 0:001 NS NS
LDL cholesterol (mg/100mL) 25:0 ± 3:8 31:4 ± 4:5 49:6 ± 6:1∗∗∗ 34:4 ± 3:9X p < 0:01 NS p < 0:05
HDL cholesterol (mg/100mL) 28:4 ± 2:0 30:8 ± 1:3 24:2 ± 0:5 34:2 ± 3:3XX NS p < 0:01 NS
AOPP (μmol/L)& 14:3 ± 1:4 17:2 ± 1:3 15:6 ± 1:5 23:2 ± 3:3∗∗X NS p < 0:05 NS
Calcium (mg/100mL) 9:97 ± 0:23 11:51 ± 0:25∗∗∗ 9:82 ± 0:27 11:86 ± 0:32∗∗∗XXX NS p < 0:001 NS
Inorganic phosphorus
(mg/100mL)
8:51 ± 0:48 4:98 ± 0:58∗∗∗ 9:40 ± 0:51 6:38 ± 0:62∗∗XXX p < 0:05 p < 0:001 NS
Bilateral ovariectomy was performed 5 weeks before the end of the experiment. Diabetes was induced 3 days after the ovariectomy by a single administration of
streptozotocin (60mg/kg i.p.). Results are presented asmeans ± SEM (n = 9 − 10). &The concentration of AOPP is presented in chloramine T equivalents. Two-
way ANOVA followed by Fisher’s LSD test was used for evaluation of the significance of the results. ∗∗p < 0:01, ∗∗∗p < 0:001—significantly different from the
NOVX control rats; Xp < 0:05, XXp < 0:01, XXXp < 0:001—significantly different from the OVX control rats; ap < 0:05, aap < 0:01—significantly different from the
DM-NOVX rats.
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Figure 1: PCA biplot of the results concerning the body mass gain and the mass of internal organs (uterus, thymus, adrenal glands, and liver)
in the diabetic and/or estrogen-deficient rats. Bilateral ovariectomy was performed 5 weeks before the end of the experiment. Diabetes was
induced 3 days after the ovariectomy by a single administration of streptozotocin (60mg/kg i.p.). Blue font and green lines indicate
correlations of measured variables against experimental groups. Shades of red denote DM rats; shades of green denote nondiabetic rats.
Darker shades and diamond symbols denote OVX rats; lighter shades and dot symbols denote NOVX rats. Group names are marked in
red fonts inside the convex hulls comprised by individuals from the same group. The statistical significance between the groups along the
PCs was analysed by two-way MANOVA. Significant results for PC1: DM—p < 0:001; OVXxDM interaction—p < 0:01; and for PC2:





























Figure 2: PCA biplot of the results concerning the concentrations of the serum biochemical metabolic parameters in the diabetic and/or
estrogen-deficient rats. Bilateral ovariectomy was performed 5 weeks before the end of the experiment. Diabetes was induced 3 days after
the ovariectomy by a single administration of streptozotocin (60mg/kg i.p.). Blue font and green lines indicate correlations of measured
variables against experimental groups. Shades of red denote DM rats; shades of green denote nondiabetic rats. Darker shades and
diamond symbols denote OVX rats; lighter shades and dot symbols denote NOVX rats. Group names are marked in red fonts inside the
convex hulls comprised by individuals from the same group. The statistical significance between the groups along the PCs was analysed by
two-way MANOVA. Significant results for PC1: OVX—p < 0:05; DM—p < 0:001, and for PC2: OVX—p < 0:001; DM—p < 0:05. Post hoc
LSD for PC2: DM-NOVX versus DM-OVX—p < 0:01. Detailed data—see Supplementary Material 1B.
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mass, and bone mineral content (the bone mineral mass/-
bone mass ratio) both in the long bones and the vertebra,
in relation to appropriate controls (Table 3, data for the tibia
not shown). For example, the bone mineral content in the
femur of the nonovariectomized diabetic rats decreased by
4.1% in comparison with the nonovariectomized controls,
and that of the ovariectomized diabetic rats—by 3.2% in com-
parison with the ovariectomized controls. Also, the femoral
length decreased. There was no effect of diabetes on the bone
content of water and organic substances, as well as on the cal-
cium content in the bone mineral. Estrogen deficiency did not
significantly affect the abovementioned parameters, with the
exception of decreasing the bone mineral content (by 2.6%)
concomitantly with increasing the bone water content in the
femur in relation to the nonovariectomized controls.
The PCA analysis indicated differences concerning the
bone mass and macrometric parameters (Figure 5) and bone
composition and mineralization (Figure 6) between the dia-
betic and nondiabetic rats.
3.4. Bone Histomorphometry. Diabetes induced deterioration
of microarchitecture of the cancellous bone of the femoral
metaphysis, regardless of the estrogen status (Figure 7). In
the nonovariectomized rats, diabetes decreased the bone vol-
ume to tissue volume ratio (BV/TV) and trabecular thickness
(Tb.Th), whereas in the ovariectomized rats—Tb.Th was
decreased and trabecular number (Tb.N) was increased due
to diabetes. Estrogen deficiency, in the nondiabetic rats,
induced significant decreases in BV/TV and Tb.N, as well
as increases in trabecular separation (Tb.Sp). The changes
in BV/TV induced by diabetes, estrogen deficiency, or both
pathologies were of similar degree (decreases by 17.3%,
13.0%, and 18.1%, respectively, in relation to the nonovariec-
tomized controls).
In cortical bone, diabetes decreased the transverse
cross-sectional area of the cortical bone (Ct.Ar) and trans-
verse cross-sectional area of the whole diaphysis (Tt.Ar),
both in the tibial and femoral diaphysis, regardless the
estrogen status (Table 4, data for the tibial diaphysis not
shown). The Ct.Ar decreased, due to diabetes, by 5.8% in
the nonovariectomized rats, and by 9.0% in the ovariecto-
mized rats, in relation to the respective control rats. Estro-
gen deficiency did not affect the histomorphometric
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Figure 3: Effects of diabetes (DM) and/or estrogen deficiency on the serum bone turnover markers (osteocalcin and CTX-I) in rats. Bilateral
ovariectomy was performed 5 weeks before the end of the experiment. Diabetes was induced 3 days after the ovariectomy by a single
administration of streptozotocin (60mg/kg i.p.). Results are presented as means ± SEM (n = 9 − 10). NOVX: nonovariectomized control
rats; DM-NOVX: rats with type 1 diabetes; OVX: ovariectomized control rats; DM-OVX: ovariectomized rats with type 1 diabetes. CTX-I:
C-terminal telopeptide fragments of type I collagen. Two-way ANOVA followed by Fisher’s LSD test was used for evaluation of the
significance of the results. ∗p < 0:05, ∗∗∗p < 0:001—significantly different from the NOVX control rats; XXXp < 0:001—significantly
different from the OVX control rats.
7Mediators of Inflammation
The PCA analysis indicated differences concerning his-
tomorphometric parameters of cancellous (Figure 8) and
compact (Figure 9) between the diabetic and nondiabetic
rats.
3.5. Bone Mechanical Properties. In the proximal tibial meta-
physis, consisting mostly of cancellous bone, diabetes
induced worsening of bone strength, regardless of the estro-
gen status (Figure 10, Table 5; data for the yield point not
shown). In the ovariectomized control rats, most of the
mechanical parameters were similar to those observed in
the nonovariectomized diabetic rats. Moreover, in the ovari-
ectomized control rats, Young’s modulus was significantly
decreased in relation to the nonovariectomized controls.
The changes in the ovariectomized diabetic rats were in most
cases less pronounced than in the nonovariectomized dia-
betic rats in relation to the appropriate nondiabetic controls,
as indicated by significant interactions concerning the
mechanical parameters of the tibial metaphysis noted in
two-way ANOVA. For example, the decreases in the maxi-
mum load induced by diabetes, estrogen deficiency, or both
pathologies were as follows: 35.4%, 34.2%, and 48.1%, respec-
tively, in relation to the nonovariectomized control rats.
However, the maximum load in the ovariectomized diabetic
rats was decreased only by 21.1% in comparison with the
ovariectomized controls.
In the femoral diaphysis, no effects of diabetes on the
extrinsic mechanical parameters were observed; however,
increases in the intrinsic parameters (Young’s modulus in
both the nonovariectomized and ovariectomized rats, stress
in the nonovariectomized rats) were observed (Table 5; data
for the yield point not shown). The value of Young’s modulus
increased due to diabetes by 21.9% in the nonovariectomized
rats and by 11.1% in the ovariectomized rats in comparison
with appropriate controls. Estrogen deficiency alone did not
affect the investigated parameters, whereas in the diabetic
rats, it decreased the value of stress in relation to the nono-
variectomized diabetic rats.
There was no effect of both diabetes and estrogen defi-
ciency on the strength of the femoral neck (not shown).
The PCA analysis indicated differences concerning the
mechanical properties of cancellous (Figure 11) and compact
bone (Figure 12) between the diabetic and nondiabetic rats.
Moreover, there were differences concerning the mechanical
properties of cancellous bone between the nonovariecto-
mized and ovariectomized rats.
3.6. Serum Cytokine Concentrations. STZ-induced diabetes
led to the development of profound changes in the serum
cytokine levels, both in the nonovariectomized and ovariec-
tomized rats (significant main diabetes effects) (Table 6).
The following cytokines were moderately (less than 5x)
increased: IL-1α, IL-4, IL-10, IL-13, IL-17A, G-CSF, IFN-γ,
M-CSF, MIP-3a, RANTES, and TNF-α, and the following
were strongly increased (more than 5x): IL-1β, IL-7, GM-
CSF, GRO/KC, MIP-1a, VEGF, and MCP-1 (MCAF). There
were no significant changes in the cytokine levels induced by
estrogen deficiency. The only significant interaction between
the main effects (OVX and DM) concerned the RANTES

























Figure 4: PCA biplot of the results concerning the concentrations of the serum bone turnover markers and concentrations of calcium and
inorganic phosphorus in the diabetic and/or estrogen-deficient rats. Bilateral ovariectomy was performed 5 weeks before the end of the
experiment. Diabetes was induced 3 days after the ovariectomy by a single administration of streptozotocin (60mg/kg i.p.). Blue font and
green lines indicate correlations of measured variables against experimental groups. Shades of red denote DM rats; shades of green denote
nondiabetic rats. Darker shades and diamond symbols denote OVX rats; lighter shades and dot symbols denote NOVX rats. Group names
are marked in red fonts inside the convex hulls comprised by individuals from the same group. The statistical significance between the
groups along the PCs was analysed by two-way MANOVA. Significant results for PC1: DM—p < 0:001, and for PC2: OVX—p < 0:01.
Detailed data—see Supplementary Material 1C.
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The PCA analysis indicated strong differences concern-
ing cytokine levels between the diabetic and nondiabetic rats,
regardless of the estrogen status (Figure 13).
4. Discussion
Although postmenopausal osteoporosis often occurs concur-
rently with diabetes, little is known about interactions
between estrogen deficiency and hyperglycemia in terms of
effects on the skeletal system in vivo.
In the present study, bilateral ovariectomy induced estro-
gen deficiency, as confirmed by characteristic changes in
estrogen-dependent organ mass (the uterus and thymus),
significant increases in the body mass gain, and serum cho-
lesterol levels. Also, osteoporotic microstructure and strength
changes due to estrogen deficiency were demonstrated five
weeks after the ovariectomy, as previously described [30,
38]. The microstructure changes concerned cancellous bone
(decreases in BV/TV and Tb.N, increases in Tb.Sp) and led
to worsening of the strength of the proximal tibial metaphy-
sis, built mostly of cancellous bone. There were no significant
changes in compact bone histomorphometric parameters
and mechanical properties (Ct.Ar, Tt.Ar, Ma.Ar in the tibial
and femoral diaphysis, and strength of the femoral diaphysis,
respectively). The bone resorption marker (CTX-I) concen-
tration tended to increase, and the bone formation marker
(osteocalcin) level significantly increased. The observed
changes are consistent with well-established mechanisms of
changes developing in the bone due to estrogen deficiency.
Estrogen deficiency increases the rate of bone remodeling,
and both bone resorption and formation accelerate. This is
because estrogen decreases the number of remodeling cycles,
inhibiting the birth rate of osteoclasts and osteoblasts from
their progenitors, and has proapoptotic effects on osteoclasts
and antiapoptotic effects on osteoblasts and osteocytes. The
loss of bone mass and strength is the result of the shift of
the balance toward bone resorption [39].
The nonovariectomized rats administered STZ developed
diabetes, with hyperglycemia, polydipsia, polyuria, character-
istic changes in the serum parameters, and decreased body
mass. Very profound changes in the skeletal system were
observed, consistent with other studies [18, 20–25]. Bone
mass, mineralization, and mechanical properties of cancel-
lous bone of the proximal tibial metaphysis profoundly
Table 3: Effects of diabetes (DM) and/or estrogen deficiency on the bone mass, macrometric parameters, composition, and mineralization in




Ovariectomized (OVX) rats Two-way ANOVA




Femur 0:682 ± 0:014 0:629 ± 0:012∗∗ 0:677 ± 0:014 0:618 ± 0:012∗∗XX NS p < 0:001 NS
L4
vertebra
0:214 ± 0:009 0:188 ± 0:008∗ 0:214 ± 0:006 0:178 ± 0:005∗∗∗XX NS p < 0:001 NS
Femoral length (mm) 33:54 ± 0:18 32:83 ± 0:16∗ 34:07 ± 0:22 32:80 ± 0:20∗∗XXX NS p < 0:001 NS
Femoral diameter (mm) 3:36 ± 0:03 3:28 ± 0:03 3:37 ± 0:04 3:26 ± 0:04 NS p < 0:01 NS
Bone mineral mass (g)
Femur 0:331 ± 0:007 0:293 ± 0:007∗∗∗ 0:320 ± 0:006 0:283 ± 0:005∗∗∗XXX NS p < 0:001 NS
L4
vertebra
0:086 ± 0:003 0:073 ± 0:003∗∗∗ 0:086 ± 0:002 0:068 ± 0:002∗∗∗XXX NS p < 0:001 NS
Bone mineral content (g/g)
Femur 0:485 ± 0:003 0:466 ± 0:006∗∗ 0:473 ± 0:004∗ 0:458 ± 0:003∗∗∗XX p < 0:05 p < 0:001 NS
L4
vertebra
0:407 ± 0:011 0:391 ± 0:008 0:403 ± 0:007 0:384 ± 0:005 NS p < 0:05 NS
Bone water content (g/g)
Femur 0:276 ± 0:004 0:294 ± 0:007 0:303 ± 0:013 0:301 ± 0:004 p < 0:05 NS NS
L4
vertebra
0:345 ± 0:014 0:362 ± 0:010 0:347 ± 0:007 0:362 ± 0:009 NS NS NS
Bone organic substances
content (g/g)
Femur 0:239 ± 0:002 0:240 ± 0:002 0:224 ± 0:012 0:241 ± 0:002 NS NS NS
L4
vertebra
0:248 ± 0:004 0:248 ± 0:003 0:250 ± 0:002 0:254 ± 0:006 NS NS NS
Calcium content (g/g of
bone mineral)
Femur 0:373 ± 0:007 0:364 ± 0:012 0:363 ± 0:007 0:377 ± 0:006 NS NS NS
L4
vertebra
0:345 ± 0:018 0:347 ± 0:016 0:346 ± 0:015 0:339 ± 0:015 NS NS NS
Phosphorus content (g/g
of bone mineral)
Femur 0:176 ± 0:003 0:173 ± 0:002 0:171 ± 0:002 0:180 ± 0:002XX a NS NS p < 0:01
L4
vertebra
0:156 ± 0:004 0:155 ± 0:003 0:158 ± 0:004 0:153 ± 0:003 NS NS NS
Bilateral ovariectomy was performed 5 weeks before the end of the experiment. Diabetes was induced 3 days after the ovariectomy by a single administration of
streptozotocin (60mg/kg i.p.). Results are presented as means ± SEM (n = 9 − 10). Two-way ANOVA followed by Fisher’s LSD test was used for evaluation of
the significance of the results. ∗p < 0:05, ∗∗p < 0:01, ∗∗∗p < 0:001—significantly different from the NOVX control rats; XXp < 0:01, XXXp < 0:001—significantly






























Figure 5: PCA biplot of the results concerning the bone mass and macrometric parameters in the diabetic and/or estrogen-deficient rats.
Bilateral ovariectomy was performed 5 weeks before the end of the experiment. Diabetes was induced 3 days after the ovariectomy by a
single administration of streptozotocin (60mg/kg i.p.). Blue font and green lines indicate correlations of measured variables against
experimental groups. Shades of red denote DM rats; shades of green denote nondiabetic rats. Darker shades and diamond symbols denote
OVX rats; lighter shades and dot symbols denote NOVX rats. Group names are marked in red fonts inside the convex hulls comprised by
individuals from the same group. The statistical significance between the groups along the PCs was analysed by two-way MANOVA.
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Figure 6: PCA biplot of the results concerning the bone composition and mineralization in the diabetic and/or estrogen-deficient rats.
Bilateral ovariectomy was performed 5 weeks before the end of the experiment. Diabetes was induced 3 days after the ovariectomy by a
single administration of streptozotocin (60mg/kg i.p.). Blue font and green lines indicate correlations of measured variables against
experimental groups. Shades of red denote DM rats; shades of green denote nondiabetic rats. Darker shades and diamond symbols denote
OVX rats; lighter shades and dot symbols denote NOVX rats. Group names are marked in red fonts inside the convex hulls comprised by
individuals from the same group. The statistical significance between the groups along the PCs was analysed by two-way MANOVA.
Significant results for PC2: DM—p < 0:01. Detailed data—see Supplementary Material 1E.
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worsened, whereas the strength of compact bone was not
decreased. In fact, significant increases in the values of intrin-
sic mechanical parameters (stress, Young’s modulus) in the
femoral diaphysis were demonstrated in the diabetic rats,
which however was rather the result of decreases in bone size
than improvement of bone quality. Deterioration of cancel-
lous bone microstructure was demonstrated (decreases in
BV/TV and Tb.Th). Bone resorption was intensified, and
bone formation was decreased as demonstrated by the mea-
surements of serum bone turnover marker concentrations
(CTX-I and osteocalcin, respectively).
The pathomechanism of the development of the skeletal
changes in diabetes is complex. There are differences between
clinical skeletal manifestations of type 1 and type 2 diabetes.
T1D leads to decreased BMD and increased fracture risk. In
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Figure 7: Effects of diabetes (DM) and/or estrogen deficiency on the histomorphometric parameters of cancellous bone of the distal femoral
metaphysis in rats. Bilateral ovariectomy was performed 5 weeks before the end of the experiment. Diabetes was induced 3 days after the
ovariectomy by a single administration of streptozotocin (60mg/kg i.p.). Results are presented as means ± SEM (n = 9 − 10). NOVX:
nonovariectomized control rats; DM-NOVX: rats with type 1 diabetes; OVX: ovariectomized control rats; DM-OVX: ovariectomized rats
with type 1 diabetes. BV/TV: bone volume to tissue volume ratio; Tb.Th: trabecular thickness; Tb.Sp: trabecular separation; Tb.N:
trabecular number. Two-way ANOVA followed by Fisher’s LSD test was used for evaluation of the significance of the results. ∗p < 0:05, ∗∗
p < 0:01—significantly different from the NOVX control rats; XXp < 0:01—significantly different from the OVX control rats.





Ovariectomized (OVX) rats Two-way ANOVA
Control DM Control DM OVX DM OVXx DM
Diaphysis
Tt.Ar (mm2) 8:21 ± 0:11 7:81 ± 0:16 8:39 ± 0:18 7:79 ± 0:13XX NS p < 0:01 NS
Ct.Ar (mm2) 5:42 ± 0:06 5:10 ± 0:08∗∗ 5:51 ± 0:08 5:02 ± 0:05∗∗∗XXX NS p < 0:001 NS
Ma.Ar (mm2) 2:79 ± 0:07 2:70 ± 0:11 2:87 ± 0:13 2:78 ± 0:10 NS NS NS
Ma.Ar/Tt.Ar 0:340 ± 0:005 0:346 ± 0:008 0:341 ± 0:009 0:355 ± 0:007 NS NS NS
Bilateral ovariectomy was performed 5 weeks before the end of the experiment. Diabetes was induced 3 days after the ovariectomy by a single administration of
streptozotocin (60mg/kg i.p.). Results are presented as means ± SEM (n = 9 − 10). Two-way ANOVA followed by Fisher’s LSD test was used for evaluation of
the significance of the results. ∗∗p < 0:01, ∗∗∗p < 0:001—significantly different from the NOVX control rats; XXp < 0:01, XXXp < 0:001—significantly different
from the OVX control rats; Tt.Ar: transverse cross-section area of the whole diaphysis; Ct.Ar: transverse cross-section area of the cortical bone; Ma.Ar:
transverse cross-section area of the marrow cavity; Ma.Ar/Tt.Ar: transverse cross-section area of the marrow cavity/diaphysis ratio.
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of fracture is also elevated [5, 6, 40]. In T1D, hyperglycemia
and the inflammatory environment influence all types of
bone cells, i.e., osteoblasts, osteocytes, and osteoclasts [41].
The mechanisms of the development of the bone changes,
demonstrated in experimental conditions, involved, among
others: intensification of osteoclast activity, decreased func-
tion of osteoblasts induced by insulin deficiency, and


























Figure 8: PCA biplot of the results concerning histomorphometric parameters of cancellous bone (the distal femoral metaphysis) in the
diabetic and/or estrogen-deficient rats. Bilateral ovariectomy was performed 5 weeks before the end of the experiment. Diabetes was
induced 3 days after the ovariectomy by a single administration of streptozotocin (60mg/kg i.p.). Blue font and green lines indicate
correlations of measured variables against experimental groups. Shades of red denote DM rats; shades of green denote nondiabetic rats.
Darker shades and diamond symbols denote OVX rats; lighter shades and dot symbols denote NOVX rats. Group names are marked in
red fonts inside the convex hulls comprised by individuals from the same group. The statistical significance between the groups along the



























Figure 9: PCA biplot of the results concerning histomorphometric parameters of compact bone (the tibial and femoral diaphysis) in the
diabetic and/or estrogen-deficient rats. Bilateral ovariectomy was performed 5 weeks before the end of the experiment. Diabetes was
induced 3 days after the ovariectomy by a single administration of streptozotocin (60mg/kg i.p.). Blue font and green lines indicate
correlations of measured variables against experimental groups. Shades of red denote DM rats; shades of green denote nondiabetic rats.
Darker shades and diamond symbols denote OVX rats; lighter shades and dot symbols denote NOVX rats. Group names are marked in
red fonts inside the convex hulls comprised by individuals from the same group. The statistical significance between the groups along the
PCs was analysed by two-way MANOVA. Significant results for PC1: DM—p < 0:05. Detailed data—see Supplementary Material 1G.
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decreased bone quality caused by advanced glycation prod-
ucts [41, 42]. Moreover, diabetes increases oxidative stress
[43, 44], which may intensify bone resorption and inhibit
bone formation [39].
Summing up, the ovariectomy and STZ administration
induced opposite actions on the body mass gain. Bone mass
and macrometric parameters were not affected by estrogen
deficiency, whereas diabetes induced significant decreases in
the bone mass, length, and femoral diaphysis cross-section
area. Nonetheless, the bone quality changes in the diabetic
rats in the present study were very similar to those develop-
ing due to estrogen deficiency. In both experimental models,
cancellous bone mechanical properties were worsened to
almost the same extent, and there was no damaging effect
on the strength of the compact bone of the femoral diaphysis.
The differences concerning cancellous bone microstructure
were slight: the decrease in BV/TV was caused by a decrease
in Tb.N with an increase in Tb.Sp in the ovariectomized con-
trol rats, whereas in the diabetic rats, by a decrease in Tb.Th.
The main difference between the models concerned the bone
turnover markers. Although both endocrine changes induced
increases in bone resorption, estrogen deficiency increased
bone formation marker concentration, whereas diabetes
decreased it. The decrease in bone formation may explain
the decrease in Tb.Th in the diabetic rats.
The skeletal effects of diabetes in the estrogen-deficient
rats were very similar to those induced in the rats with nor-
mal estrogen levels (nonovariectomized). No further
decrease in BV/TV was demonstrated, and Tb.Th decreased
and Tb.N increased in relation to the ovariectomized control
rats. However, further deterioration in the mechanical prop-
erties of cancellous bone compared to the estrogen-deficient
control rats was observed. Similarly to the effects in the non-
ovariectomized rats, diabetes induced an increase in Young’s
modulus of the femoral diaphysis (compact bone) of the
ovariectomized rats; however, no increases in the stress
values were demonstrated. The bone resorption marker
(CTX-I) further increased, and bone formation marker
(osteocalcin) strongly decreased in relation to both the ovari-
ectomized and nonovariectomized control rats. These obser-
vations are partially at variance with those of Liu et al. [25]
who concluded, based on microstructural and gene expres-
sion studies, that STZ-induced diabetes, in estrogen-
deficient rats, reversed high bone turnover osteoporosis into
low bone turnover one (decreases in both formation and
bone resorption indices), with stronger microstructure
changes and bone loss. On the other hand, Wen et al. [20]
reported increasing effects of concurrent diabetes and estro-
gen deficiency on the rat serum bone turnover markers and
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Figure 10: Effects of diabetes (DM) and/or estrogen deficiency on the mechanical properties of cancellous bone (the proximal tibial
metaphysis – data for the maximum load point) in rats. Bilateral ovariectomy was performed 5 weeks before the end of the experiment.
Diabetes was induced 3 days after the ovariectomy by a single administration of streptozotocin (60mg/kg i.p.). Results are presented as
means ± SEM (n = 9 − 10). NOVX: nonovariectomized control rats; DM-NOVX: rats with type 1 diabetes; OVX: ovariectomized control
rats; DM-OVX: ovariectomized rats with type 1 diabetes. Two-way ANOVA followed by Fisher’s LSD test was used for evaluation of the
significance of the results. ∗p < 0:05, ∗∗p < 0:01, ∗∗∗p < 0:001—significantly different from the NOVX control rats; Xp < 0:05, XXp < 0:01,
XXXp < 0:001—significantly different from the OVX control rats.
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the effects induced by estrogen deficiency alone (whereas in
diabetes alone, bone formation indices were decreased).
The mouse studies indicated possible roles of renin-
angiotensin and kallikrein-kinin systems [24] and increased
expression of TNF-α [23] in the development of osteoporotic
changes induced by diabetes and estrogen deficiency.
There are few studies that investigated bone mechanical
properties in diabetic osteoporotic animals. As far as
mechanical properties of cortical bone are concerned, de
Mello-Sampayo et al. [22] reported on the favorable effect
of hyperglycemia on the femoral strength, since the values
of ultimate stress and Young’s modulus increased in
estrogen-deficient diabetic rats. We also observed increases
in Young’s modulus values for the femoral diaphysis of the
diabetic rats, regardless of the estrogen status. Also, the max-
imum stress increased, but only in the nonovariectomized
diabetic rats. The lack of such an effect in the estrogen-
deficient rats does not support the hypothesis on the favor-
able effects of diabetes (hyperglycemia) on the mechanical
properties of cortical bone. Moreover, it should be stressed
that diabetes induced strong harmful effect on the mechani-
cal properties of the cancellous bone of the tibial metaphysis,
both in the nonovariectomized and ovariectomized rats. Sim-
ilarly to our results for cancellous bone, no significant differ-
ences between the L4 vertebra strength of nonovariectomized
and ovariectomized diabetic rats were observed by Lee et al.
[21] (the effects of estrogen deficiency alone were not inves-
tigated in that study).
The differences between the results concerning the effects
of diabetes and estrogen deficiency on the skeletal system in
different studies might have resulted from differences in the
study designs. Stronger than in the present study aggravation
of damaging effects of both pathologies over those induced by
them separately were reported by other authors in mouse
models [23, 24] or after longer periods of observation in rats
[20, 21, 25]. However, the measurements were performed five
weeks after the ovariectomy in the present study. Such a
period in adult rats corresponds to about three years in
humans [45]. The period of four-five weeks was long enough
to demonstrate the effects of different treatments or estrogen
deficiency on the skeletal system in rats in our previous stud-
ies [30, 38].
There are interactions between estrogen deficiency and
energy metabolism. For example, it has been reported that
long-term estrogen deficiency leads to the decline of whole-
body glucose metabolism in ovariectomized rats [46]. How-
ever, based on the results of the present study, it seems that
estrogen deficiency exerts very slight effects on the changes
induced by diabetes in the rat skeletal system. This seems to
agree with the lack of data on the effect of diabetes on post-
menopausal osteoporosis in women. Consistently, it has been
reported that, in patients, the presence of diabetes did not
Table 5: Effects of diabetes (DM) and/or estrogen deficiency on the mechanical properties of cancellous (the proximal tibial metaphysis) and




Ovariectomized (OVX) rats Two-way ANOVA




Young’s modulus (MPa) 4063 ± 430 3269 ± 390 2713 ± 248∗∗ 3169 ± 182 p < 0:05 NS NS
Fracture point load (N) 89:5 ± 7:5 54:5 ± 5:0∗∗∗ 60:0 ± 2:8∗∗∗ 43:6 ± 2:2
∗∗∗
X p < 0:001 p < 0:001 NS
Displacement for fracture point
load (mm)
1:068 ± 0:054 1:004 ± 0:088 1:208 ± 0:074 0:953 ± 0:087 NS p < 0:05 NS
Energy for fracture point load (mJ) 80:8 ± 5:7 49:9 ± 7:0∗∗∗ 63:9 ± 5:0∗ 40:7 ± 3:9
∗∗∗
XX p < 0:05 p < 0:001 NS
Stress for fracture point load (MPa) 74:1 ± 7:8 47:3 ± 4:8∗∗∗ 47:4 ± 4:2∗∗∗ 35:6 ± 1:3∗∗∗ p < 0:001 p < 0:001 NS
Femur
Young’s modulus (MPa) 8929 ± 242 10886 ± 373∗∗∗ 8957 ± 418 9955 ± 333∗X NS p < 0:001 NS
Maximum load (N) 124:8 ± 4:3 125:8 ± 3:8 130:1 ± 3:7 119:3 ± 5:3 NS NS NS
Displacement for maximum load
(mm)
0:502 ± 0:021 0:493 ± 0:019 0:516 ± 0:034 0:487 ± 0:016 NS NS NS
Energy for maximum load (mJ) 38:0 ± 2:8 38:2 ± 2:4 41:0 ± 3:7 35:7 ± 2:6 NS NS NS
Stress for maximum load (MPa) 168:9 ± 4:2 189:7 ± 4:9∗∗ 171:2 ± 4:3 174:6 ± 5:7a NS p < 0:05 NS
Fracture point load (N) 123:3 ± 4:4 124:8 ± 3:6 129:4 ± 3:8 118:3 ± 5:2 NS NS NS
Displacement for fracture point
load (mm)
0:517 ± 0:021 0:505 ± 0:021 0:524 ± 0:034 0:501 ± 0:019 NS NS NS
Energy for fracture point load (mJ) 39:8 ± 2:9 39:8 ± 2:6 42:0 ± 3:8 37:5 ± 3:2 NS NS NS
Stress for fracture point load (MPa) 166:8 ± 4:6 188:1 ± 4:6∗∗ 170:3 ± 4:4 173:1 ± 5:7a NS p < 0:05 NS
Bilateral ovariectomy was performed 5 weeks before the end of the experiment. Diabetes was induced 3 days after the ovariectomy by a single administration of
streptozotocin (60mg/kg i.p.). Results are presented as means ± SEM (n = 9 − 10). Two-way ANOVA followed by Fisher’s LSD test was used for evaluation of
the significance of the results. ∗p < 0:05, ∗∗p < 0:01, ∗∗∗p < 0:001—significantly different from the NOVX control rats; Xp < 0:05, XXp < 0:01—significantly
different from the OVX control rats; ap < 0:05—significantly different from the DM-NOVX rats.
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Figure 11: PCA biplot of the results concerning mechanical properties of cancellous bone (the proximal tibial metaphysis) in the diabetic
and/or estrogen-deficient rats. Bilateral ovariectomy was performed 5 weeks before the end of the experiment. Diabetes was induced 3
days after the ovariectomy by a single administration of streptozotocin (60mg/kg i.p.). Blue font and green lines indicate correlations of
measured variables against experimental groups. Shades of red denote DM rats; shades of green denote nondiabetic rats. Darker shades
and diamond symbols denote OVX rats; lighter shades and dot symbols denote NOVX rats. Group names are marked in red fonts inside
the convex hulls comprised by individuals from the same group. The statistical significance between the groups along the PCs was
analysed by two-way MANOVA. Significant results for PC1: OVX—p < 0:001; DM—p < 0:001. Detailed data—see Supplementary
Material 1H.
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Figure 12: PCA biplot of the results concerning mechanical properties of compact bone (the femoral diaphysis) in the diabetic and/or
estrogen-deficient rats. Bilateral ovariectomy was performed 5 weeks before the end of the experiment. Diabetes was induced 3 days after
the ovariectomy by a single administration of streptozotocin (60mg/kg i.p.). Blue font and green lines indicate correlations of measured
variables against experimental groups. Shades of red denote DM rats; shades of green denote nondiabetic rats. Darker shades and
diamond symbols denote OVX rats; lighter shades and dot symbols denote NOVX rats. Group names are marked in red fonts inside the
convex hulls comprised by individuals from the same group. The statistical significance between the groups along the PCs was analysed by
two-way MANOVA. Significant results for PC2: DM—p < 0:01. Detailed data—see Supplementary Material 1I.
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affect response to different antiosteoporotic drugs, regarding
BMD increase and vertebral fracture risk reduction [47].
To evaluate the background of the skeletal changes
observed in the present study, serum concentrations of a
wide panel of cytokines was evaluated. Cytokines play major
roles in numerous autoimmune diseases, hypersensitivity
reactions, and pathologic conditions, like rheumatoid arthri-
tis, dermatitis, asthma, and insulin-dependent diabetes [48].
Although cytokines mostly act locally, changes in their blood
concentrations may exert general effects. It is likely that they
are involved in the development of osteoporosis. Although
no significant differences between the plasma levels of ten
investigated cytokines in postmenopausal women with nor-
mal and low BMD were reported [49], some changes in cyto-
kine profiles were demonstrated using advanced statistical
methods [48].
The relationships between cytokines released by bone
(osteoblasts, osteocytes, and osteoclasts) and immune cells
are extremely complex and not fully recognized [50]. Apart
from the best known RANKL/osteoprotegerin axis, the cyto-
kines known to regulate the proliferation, differentiation, and
functions of osteoblastic and osteoclastic cells, include,
among others, proosteoclastogenic cytokines, stimulating
bone resorption (M-CSF, TNF-α, IL-1, IL-6, IL-8, and IL-
17), and antiosteoclastogenic cytokines (transforming
growth factor β (TGF-β), IFN-γ, IL-4, IL-10, and IL-12)
[51, 52]. A shift in general immune balance towards an acti-
vated inflammatory immune status is considered a risk factor
for osteoporosis [48]. Also, in diabetes, numerous changes in
cytokine levels are observed [53, 54].
In the present study, no significant effect of estrogen defi-
ciency on the examined cytokine levels was demonstrated. It
has been suggested for many years that estrogen deficiency is
connected with low-grade inflammation and increased levels
of proinflammatory cytokines [55, 56]. However, our results
are consistent with results concerning the evaluation of ten
cytokines in postmenopausal women mentioned above
[49]. They are also consistent with the study of Russell et al.
[57], in which a lack of effect of estradiol administration on
the serum levels of most of 24 cytokines was demonstrated
in estrogen-deficient rats. It is possible that the estrogen
deficiency-induced effects on serum cytokine levels need
Table 6: Effects of diabetes (DM) and/or estrogen deficiency on the serum concentrations of cytokines in rats.
Parameter/group
Nonovariectomized (NOVX) rats Ovariectomized (OVX) rats Two-way ANOVA
Control DM Control DM OVX DM OVXx DM
IL-1α (pg/mL) 174:0 ± 25:7 366:7 ± 64:9∗∗ 180:3 ± 34:9 362:1 ± 42:9∗∗XX NS p < 0:001 NS
IL-1β (pg/mL) 613:6 ± 155:9 43675 ± 23833 495:5 ± 138:5 29915 ± 22082 NS p < 0:05 NS
IL-2 (pg/mL) 585:7 ± 260:4 2670 ± 1394 419:3 ± 141:9 743:9 ± 377:8 NS NS NS
IL-4 (pg/mL) 105:9 ± 19:9 233:7 ± 37:8∗∗ 106:6 ± 22:9 152:3 ± 19:9a NS p < 0:01 NS
IL-5 (pg/mL) 565:7 ± 39:6 649:2 ± 42:1 543:4 ± 49:2 610:9 ± 78:6 NS NS NS
IL-6 (pg/mL) 470:5 ± 214:2 750:6 ± 185:5 379:1 ± 86:4 635:2 ± 158:5 NS NS NS
IL-7 (pg/mL) 506:5 ± 108:7 5886 ± 1750∗∗ 426:7 ± 91:8 5168 ± 1873∗X NS p < 0:001 NS
IL-10 (pg/mL) 84:8 ± 15:0 193:2 ± 33:5∗∗ 80:8 ± 18:0 170:8 ± 29:3∗X NS p < 0:001 NS
IL-12p70 (pg/mL) 250:4 ± 62:7 307:5 ± 57:7 274:3 ± 92:3 324:2 ± 75:2 NS NS NS
IL-13 (pg/mL) 139:2 ± 25:5 424:1 ± 140:4 128:2 ± 35:1 209:2 ± 63:7 NS p < 0:05 NS
IL-17A (pg/mL) 62:3 ± 9:0 95:6 ± 19:7 61:9 ± 12:7 110:4 ± 19:2 NS p < 0:05 NS
IL-18 (pg/mL) 3950 ± 851 10802 ± 5377 4341 ± 208 4663 ± 1651 NS NS NS
G-CSF (pg/ml) 2:16 ± 0:77 5:98 ± 2:07 1:56 ± 0:72 5:45 ± 1:65 NS p < 0:05 NS
GM-CSF (pg/ml) 874:2 ± 224:5 26206 ± 7878∗∗ 793:5 ± 216:4 22875 ± 6940∗∗XX NS p < 0:001 NS
GRO/KC (pg/ml) 627:1 ± 65:4 12186 ± 6622 659:9 ± 178:6 6295 ± 2398 NS p < 0:05 NS
IFN-γ (pg/ml) 308:6 ± 50:8 618:8 ± 146:8 293:8 ± 76:3 459:3 ± 87:4 NS p < 0:05 NS
M-CSF (pg/ml) 22:8 ± 5:4 55:3 ± 12:2∗∗ 15:8 ± 3:8 51:7 ± 8:4∗XX NS p < 0:001 NS
MIP-1a (pg/ml) 206:8 ± 56:5 10541 ± 2459∗∗∗ 157:7 ± 35:3 10720 ± 2032∗∗∗XXX NS p < 0:001 NS
MIP-3a (pg/ml) 28:6 ± 4:1 106:5 ± 13:9 26:3 ± 4:9 206:4 ± 67:2∗∗XX NS p < 0:01 NS
RANTES (pg/ml) 2011 ± 214 2192 ± 223 2204 ± 813 8095 ± 1414∗∗∗XXX aaa p < 0:01 p < 0:01 p < 0:01
TNF-α (pg/ml) 326:4 ± 108:6 457:4 ± 88:1 254:4 ± 81:3 623:0 ± 127:6 NS p < 0:05 NS
VEGF (pg/ml) 486:8 ± 67:0 7360 ± 2916∗∗ 608:9 ± 122:2 4020 ± 991 NS p < 0:01 NS
MCP-1 (MCAF) (pg/ml) 3119 ± 493 834106 ± 241089∗∗∗ 4110 ± 1334 598440 ± 159609∗∗XX NS p < 0:001 NS
Bilateral ovariectomy was performed 5 weeks before the end of the experiment. Diabetes was induced 3 days after the ovariectomy by a single administration of
streptozotocin (60mg/kg i.p.). Results are presented as means ± SEM (n = 7). Two-way ANOVA followed by Fisher’s LSD test was used for evaluation of the
significance of the results. ∗p < 0:05, ∗∗p < 0:01, ∗∗∗p < 0:001—significantly different from the NOVX control rats; Xp < 0:05, XXp < 0:01, XXXp < 0:001
—significantly different from the OVX control rats; ap < 0:05, aaap < 0:001—significantly different from the DM-NOVX rats.
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more time to develop, since significant changes in the IL-1α,
IL-6, and IFN-γ levels 3 months after ovariectomy were
reported [58]. The diabetic rats, on the other hand, had
increased levels of both proinflammatory and anti-
inflammatory cytokines. The latter was probably the effect
of compensatory mechanisms. It has been previously demon-
strated that both estrogen deficiency and diabetes increased
the bone expression of TNF-α mRNA in mice; the effect
observed in diabetic mice was strongly intensified by estro-
gen deficiency [23]. Also in our study, the serum TNF-α con-
centration was the highest in the ovariectomized diabetic rats
(however, the differences were insignificant).
An interesting observation of the present study is that the
serum RANTES concentration was increased mainly in the
ovariectomized diabetic rats. RANTES is a chemoattractant
cytokine (chemokine). RANTES is, among others, secreted
by osteoblasts and osteoclasts and promotes both osteoblast
and osteoclast migration (with no effect on bone resorption),
favoring bone formation [59]. An exceptional cytokine pat-
tern with increased levels of RANTES and no significant
effects on those of IL-6 and TNF-α was observed in fatty
degenerative osteolysis/osteonecrosis in the jawbone [60].
Plasma RANTES has been proposed as a marker of the ath-
erosclerotic process [61]. There is a report on the increased
serum level of RANTES in osteoporotic patients [62]. It
seems that the elevation of the serum RANTES concentration
in the ovariectomized diabetic rats may be a compensatory
reaction to strong inhibition of bone formation and an
increase in bone resorption.
To better understand the interactions between diabetes-
and estrogen deficiency-induced skeletal changes, the princi-
pal component analysis (PCA) was conducted on the obtained
results. PCA is a multivariate technique where individual
observations of variables in combined datasets are trans-
formed into composite principal components (PCs) through
data reduction. That allows for spatial differentiation of sam-
ples into clusters. The clusters separate in accordance with
the differences observed in measured variables across the
plane or multidimensional space built-up by two or more
PCs [37, 63]. Since multiple variables take part in the PCA,
their impact on the observed clustering and distance between
clusters is not equal [37]. Unlike quantitative-only comparison
of values for individual variables in datasets through analysis
of variance (ANOVA), the PCA provides ranks which serve
as an auxiliary qualitative information. The results of PCA
clearly indicate significant effects of diabetes or estrogen defi-
ciency on all the investigated groups of results. Also, differ-
ences concerning some general parameters (body mass and
mass of internal organs, serum biochemical parameters)
between the nonovariectomized and ovariectomized diabetic
rats were observed. However, no interactions indicating differ-
ences in the skeletal or cytokine changes induced by diabetes
depending on the estrogen status were demonstrated.
It must be noted that the effects of diabetes on numerous
cytokine levels, regardless of the estrogen status, were very
strong. Although the skeletal effects concerning the quality
of bone (mechanical properties) induced by diabetes were
similar to those induced by estrogen deficiency, the systemic
diabetes effects, as indicated by profound changes in the cyto-
kine levels, were much bigger.
Very strong effects of STZ-induced diabetes on cytokine

































Figure 13: PCA biplot of the results concerning the serum concentrations of 23 cytokines in the diabetic and/or estrogen deficiency rats.
Bilateral ovariectomy was performed 5 weeks before the end of the experiment. Diabetes was induced 3 days after the ovariectomy by a
single administration of streptozotocin (60mg/kg i.p.). Blue font and green lines indicate correlations of measured variables against
experimental groups. Shades of red denote DM rats; shades of green denote nondiabetic rats. Darker shades and diamond symbols denote
OVX rats; lighter shades and dot symbols denote NOVX rats. Group names are marked in red fonts inside the convex hulls comprised by
individuals from the same group. The statistical significance between the groups along the PCs was analysed by two-way MANOVA.
Significant results for PC1: DM—p < 0:001, and for PC2: DM—p < 0:05. Detailed data—see Supplementary Material 1J.
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relevant to those observed in diabetic patients, since patients
with T1D are treated with insulin. This seems to be the main
limitation of the study. However, it has been reported that, in
experimental conditions, the administration of insulin
improves not only glycemia but also the bone status [64].
Another limitation of the study is that it was performed on
young adult rats, whereas osteoporosis is predominantly a
disease of the elderly. Also, it is possible that the use of an
isoflavone-free (soy-free diet), instead of a standard labora-
tory diet, used in the present study, might provide more sig-
nificant results concerning cytokine levels in estrogen-
deficient rats [57]. Nevertheless, the results of the present
study indicate that the model of STZ-induced diabetes,
widely used in experimental pharmacology to investigate
the effects of different potential antidiabetic treatments,
may be too aggressive to mirror the clinical settings.
Although the effects of type 1 and type 2 diabetes on the
skeletal system in humans are differential, we observed strik-
ing similarities in the effects on bone microstructure,
mechanical properties, and serum bone turnover markers
in rats with experimental T1D induced by STZ and T2D
induced by high-fat diet and low-dose STZ [32, 65–67]. On
the other hand, similar results, concerning decreased bone
turnover, to those demonstrated for ovariectomized rats with
T1D [25] were obtained in ovariectomized Goto-Kakizaki
rats with T2D [26]. Thus, the observations from the present
study may be relevant in relation to experimental T2D.
5. Conclusions
In conclusion, the unfavorable skeletal changes induced by
diabetes in female rats were only slightly intensified by estro-
gen deficiency. Despite similar effects on bone microstruc-
ture and strength, the influence of STZ-induced T1D on the
skeletal system was based on much more profound changes
in systemic homeostasis than those induced by estrogen
deficiency.
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